Agenus Q1 net loss $70.9M; botensilimab combo shows 63% 12-month OS in colorectal cancer

AGENUS INC

2023-Q1 EPS reported -$0.22 revenue$22,902,000

Revenue $22.9M, net loss $70.9M ($0.22 EPS) vs loss $50.6M ($0.19 EPS) year ago.
Cash & investments $189.2M at March 31; raised $13.6M in ATM sales post-quarter.
Botensilimab/balstilimab: 63% 12-month OS in non-MSI-H CRC (vs 25% SOC); 33% ORR in platinum-resistant ovarian cancer.
FDA granted Fast Track for botensilimab/balstilimab in non-MSI-H/dMMR mCRC without active liver metastases.
Distributed ~5M MiNK shares (NASDAQ: INKT) as dividend to AGEN shareholders on May 1, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AGENUS INC reported the first quarter ended March 31, 2023 results: revenue $22.9 million, net income $70.9 million, EPS $0.22 per share.

Period: the first quarter ended March 31, 2023
Revenue: $22.9 million
Net income: $70.9 million
EPS: $0.22 per share
Result: reported results

Exact text from the filing

For the first quarter ended March 31, 2023, we recognized revenue of $22.9 million and incurred a net loss of $70.9 million (including non-cash expenses of $24.9 million) or $0.22 per share.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001157523-23-000779

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.